153 related articles for article (PubMed ID: 37855126)
1. Targeting Angiotensinogen With
Ye D; Cruz-López EO; Tu HC; Zlatev I; Danser AHJ
Arterioscler Thromb Vasc Biol; 2023 Dec; 43(12):2256-2264. PubMed ID: 37855126
[TBL] [Abstract][Full Text] [Related]
2. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease.
Cruz-López EO; Ye D; Wu C; Lu HS; Uijl E; Mirabito Colafella KM; Danser AHJ
Hypertension; 2022 Oct; 79(10):2115-2126. PubMed ID: 35904033
[TBL] [Abstract][Full Text] [Related]
3. Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.
Mullick AE; Yeh ST; Graham MJ; Engelhardt JA; Prakash TP; Crooke RM
Hypertension; 2017 Sep; 70(3):566-576. PubMed ID: 28716988
[TBL] [Abstract][Full Text] [Related]
4. Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.
Lo CS; Liu F; Shi Y; Maachi H; Chenier I; Godin N; Filep JG; Ingelfinger JR; Zhang SL; Chan JS
Am J Physiol Renal Physiol; 2012 Apr; 302(7):F840-52. PubMed ID: 22205225
[TBL] [Abstract][Full Text] [Related]
5. Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR.
Ye D; Cruz-López EO; Veghel RV; Garrelds IM; Kasper A; Wassarman K; Tu HC; Zlatev I; Danser AHJ
Hypertension; 2024 Jul; 81(7):1491-1499. PubMed ID: 38690653
[TBL] [Abstract][Full Text] [Related]
6. Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics.
Addison ML; Ranasinghe P; Webb DJ
Hypertension; 2023 Nov; 80(11):2243-2254. PubMed ID: 37706295
[TBL] [Abstract][Full Text] [Related]
7. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
Peng JF; Kimura B; Fregly MJ; Phillips MI
Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
[TBL] [Abstract][Full Text] [Related]
8. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.
Uijl E; Mirabito Colafella KM; Sun Y; Ren L; van Veghel R; Garrelds IM; de Vries R; Poglitsch M; Zlatev I; Kim JB; Hoorn EJ; Foster D; Danser AHJ
Hypertension; 2019 Jun; 73(6):1249-1257. PubMed ID: 31030610
[TBL] [Abstract][Full Text] [Related]
9. The renin-angiotensin-aldosterone system and its therapeutic targets.
Mirabito Colafella KM; Bovée DM; Danser AHJ
Exp Eye Res; 2019 Sep; 186():107680. PubMed ID: 31129252
[TBL] [Abstract][Full Text] [Related]
10. Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension.
Olearczyk J; Gao S; Eybye M; Yendluri S; Andrews L; Bartz S; Cully D; Tadin-Strapps M
Hypertens Res; 2014 May; 37(5):405-12. PubMed ID: 24335718
[TBL] [Abstract][Full Text] [Related]
11. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
Scott BB; McGeehan GM; Harrison RK
Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
[TBL] [Abstract][Full Text] [Related]
12. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
13. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Arendse LB; Danser AHJ; Poglitsch M; Touyz RM; Burnett JC; Llorens-Cortes C; Ehlers MR; Sturrock ED
Pharmacol Rev; 2019 Oct; 71(4):539-570. PubMed ID: 31537750
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
Narita I; Goto S; Saito N; Song J; Omori K; Kondo D; Sakatsume M; Gejyo F
Kidney Int; 2003 Sep; 64(3):1050-8. PubMed ID: 12911556
[TBL] [Abstract][Full Text] [Related]
16. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
17. Activation of the renin-angiotensin system by a low-salt diet does not augment intratubular angiotensinogen and angiotensin II in rats.
Shao W; Seth DM; Prieto MC; Kobori H; Navar LG
Am J Physiol Renal Physiol; 2013 Mar; 304(5):F505-14. PubMed ID: 23303412
[TBL] [Abstract][Full Text] [Related]
18. Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands.
Cano IP; Dionisio TJ; Cestari TM; Calvo AM; Colombini-Ishikiriama BL; Faria FAC; Siqueira WL; Santos CF
PLoS One; 2019; 14(5):e0217030. PubMed ID: 31116771
[TBL] [Abstract][Full Text] [Related]
19. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma.
Juillerat-Jeanneret L; Celerier J; Chapuis Bernasconi C; Nguyen G; Wostl W; Maerki HP; Janzer RC; Corvol P; Gasc JM
Br J Cancer; 2004 Mar; 90(5):1059-68. PubMed ID: 14997208
[TBL] [Abstract][Full Text] [Related]
20. Angiotensinogen Exerts Effects Independent of Angiotensin II.
Lu H; Wu C; Howatt DA; Balakrishnan A; Moorleghen JJ; Chen X; Zhao M; Graham MJ; Mullick AE; Crooke RM; Feldman DL; Cassis LA; Vander Kooi CW; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):256-65. PubMed ID: 26681751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
